Veracyte | VCYT

Peers Price Chg Day Year Date
A Agilent 136.33 -1.22 -0.89% 2.41% Apr/25
ARWR Arrowhead Research 21.85 -1.45 -6.22% -38.49% Apr/25
BRKR Bruker 80.53 -1.67 -2.03% 3.92% Apr/25
EXAS Exact Sciences 58.79 -4.45 -7.04% -6.21% Apr/25
ILMN Illumina 121.03 -1.85 -1.51% -42.63% Apr/25
LGND Ligand Pharmaceuticals 70.33 -0.67 -0.94% -9.33% Apr/25
LH Laboratory Of America 198.49 -9.35 -4.50% -10.49% Apr/25
MYGN Myriad Genetics 17.99 -0.64 -3.44% -14.25% Apr/25
ROG Roche Holding 219.40 0.60 0.27% -20.56% Apr/26
SHL Sonic Healthcare 26.34 -0.40 -1.50% -26.18% Apr/26
SIE Siemens 175.06 1.36 0.78% 18.80% Apr/26
TMO Thermo Fisher Scientific 571.73 -6.35 -1.10% 7.24% Apr/25
VCYT Veracyte 19.48 -0.42 -2.11% -11.33% Apr/25
WAT Waters 308.53 -1.57 -0.51% 5.40% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
RTY US2000 1981 -14.31 -0.72% 13.13% Apr/26

Veracyte traded at $19.48 this Thursday April 25th, decreasing $0.42 or 2.11 percent since the previous trading session. Looking back, over the last four weeks, Veracyte lost 7.94 percent. Over the last 12 months, its price fell by 11.33 percent. Looking ahead, we forecast Veracyte to be priced at 21.74 by the end of this quarter and at 20.51 in one year, according to Trading Economics global macro models projections and analysts expectations.

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.